Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Welcome and Introduction to Vi3C

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Peter Clark, MA, MD, FRCP: A Payer Perspective

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement

Jan

26

Today In Oncology

Leader in Global Cancer Care, Paul E. Goss, MD, PhD, Dies at 70

New Report Shows Colorectal Cancer is Now Leading Cancer Death Among Those Under 50

Pembrolizumab Plus Lenvatinib in Recurrent Gynecologic Clear Cell Carcinoma

Cabozantinib and Temozolomide in Unresectable or Metastatic Leiomyosarcoma

Nutrition Muscle Loss Compromises Survival in Patients With Cervical Cancer Undergoing Chemoradiotherapy

Advertisement

© 2026 HSP News Service, L.L.C.